Therapeutic uses for topically applied imiquimod
Imiquimod 5% cream is an imidazoquinoline amine and is a novel synthetic immune response modifier (IRM). By increasing the production of certain cytokines, it enhances the body’s innate immunity and cell-mediated immunity, which results in viral and tumour death. Several large studies have demonstrated its efficacy in the treatment of cutaneous malignancies and precancers. Recently, it has been approved for the topical treatment of small, superficial basal cell carcinomas. Significant evidence is accumulating of its efficacy in other skin conditions, such as actinic keratoses, Bowen’s disease, lentigo maligna, warts and molluscum contagiosum.
Dermatology in practice 2005; 13(4): 6–8
To continue reading this article, please sign in or register.